Key Highlights
● Returned to GAAP profit in the third quarter
● Revenue rose sharply on membership growth
● Lower end of full-year targets was raised
● Guidance implies a weaker final quarter
Among US healthcare stocks reporting recently, Clover Health Investments, Corp. (NASDAQ:CLOV) offered a results package that combined rapid expansion with a return to GAAP profit. The Medicare Advantage insurer and physician enablement technology company said that total Revenue in the third quarter climbed by more than half from the prior-year period, and that GAAP Net Income replaced the net loss recorded a year earlier. The company also improved its full-year guidance across every metric it tracks.
The release, as filed with the US Securities and Exchange Commission, showed adjusted EBITDA rising many times over from the small figure posted in the comparable period, while adjusted net income climbed by a similar order of magnitude. Consolidated gross profit, a non-GAAP measure the company favors, rose by well over half. Taken together, the figures describe a Business whose Earnings grew faster than its Top Line during the quarter, even as its overhead also expanded.
The diluted per-share result moved from a loss to a small profit. The per-share figure stayed modest in absolute terms, which reflects the thin Margin that characterizes the quarter rather than a lack of scale, since revenue has reached a far larger base than a year ago.
Chief Executive Andrew Toy said the results "further demonstrate" the company's "technology-powered differentiation," and linked "earlier and better care management" with "market-leading growth, and increasing profitability." Chief Financial Officer Clay Thornton said the company expects to deliver its "first full year of GAAP Net Income profitability," a milestone that would mark a clear shift from the losses shown in the prior year's comparable period.
Membership Is Doing the Heavy Lifting
The top-line gain traces back to enrollment. Average Medicare Advantage membership in the third quarter rose by close to half from a year earlier, and the count of insurance members at the end of September stood well above the level recorded a year before. The year-to-date picture looks much the same, with average membership and revenue both up sharply. Revenue growth ran somewhat ahead of membership growth in the period, which indicates that the premium base expanded faster than the headcount alone.
Management links the profit outlook to the age of that membership base. Thornton referred to the company's "largest member cohorts maturing" and tied that process, along with "continued operating leverage" and "strong Star ratings performance," to a view that the business is "well positioned for meaningful earnings expansion" next year. That statement is a management expectation rather than a reported result, and the release lists numerous factors that could cause outcomes to differ.
The membership concentration is also notable. The release says nearly all current members sit in the company's flagship PPO plan, and an independent count from trade publication market data Payer Issues points the same way. Market commentary listed the Clover contract with an enrollment figure, as of the start of September, that accounts for the overwhelming share of the insurer's quarter-end membership. That concentration means a single contract carries most of the economic weight of the franchise, which raises the importance of that contract's quality rating.
Reading the Benefits Expense Ratio
Clover Health reports an insurance benefits expense ratio, or BER, rather than a conventional medical care ratio. The company defines it as insurance net medical claims incurred plus quality improvement expenses, divided by net premiums earned. Quality improvement spending covers items such as health information technology, wellness and prevention programs, readmission reduction initiatives and a member rewards program. A lower ratio means a smaller share of premium dollars went toward medical costs and those quality programs.
The ratio improved from the prior-year period for both the third quarter and the year-to-date span, with the quarterly improvement being the larger of the pair. The release does not attribute the change to a specific cause, so any explanation beyond the arithmetic would be speculation. It also discontinued the normalized version of this metric at the start of this year, saying management no longer uses that measure to evaluate performance or allocate resources.
One detail stands out when the columns are compared. The third-quarter ratio sat noticeably above the year-to-date ratio, which means the summer quarter was more expensive relative to premiums than the earlier part of the year. The year-over-year improvement is not the same as a sequential one, and the year-to-date level gives a fuller sense of how the book has performed across the calendar so far.
Overhead Grew, but Unevenly
Selling, general and administrative expense rose by about a quarter in the third quarter. The adjusted version of that line, which strips out stock-based compensation and non-recurring legal expenses and settlements, rose by more than half. The gap between those growth rates is explained in part by the release's own reconciliation: stock-based compensation fell sharply from the prior-year quarter, while non-recurring legal costs moved from a negligible benefit to a small expense.
Adjusted overhead as a share of revenue edged higher in the quarter, yet it fell across the year-to-date period. The company uses this ratio to measure Operating Leverage as revenue scales, so the readings send somewhat different messages. The year-to-date decline supports the leverage narrative, while the quarterly uptick is a reminder that leverage rarely arrives in a straight line, particularly when an insurer is preparing for an enrollment season. The release does not give a reason for the quarterly movement.
Stock-based compensation is a useful line for anyone comparing GAAP and adjusted results. Because it dropped so much from the year-ago quarter, it contributed to the improvement in GAAP net income, in addition to the operating gains shown in consolidated gross profit.
The Arithmetic Behind the Raised Guidance
Clover Health raised the lower end of its full-year ranges while leaving the upper ends unchanged. That pattern applies to average Medicare Advantage membership, total revenue, GAAP net income, consolidated Gross Profit and adjusted EBITDA. In practice, management narrowed each range toward its stronger half, with less room now assumed for a weak outcome rather than any increase in the highest case.
A comparison of the guidance with the year-to-date figures adds an important layer. GAAP net income through the end of September already exceeds the top of the full-year range, and the same is true for adjusted EBITDA. Taken at face value, the guidance therefore implies that the company expects a loss in the final quarter on both measures. This is an inference from the published tables, not a statement the release makes in the sections reviewed, but it is simple subtraction and it tempers the headline about a profitable year.
Revenue and consolidated gross profit tell a less dramatic story. Year-to-date revenue leaves a final-quarter contribution in line with the recent run rate, and the gross profit guidance leaves room for a smaller contribution than the earlier quarters. Earlier in the year the BER also ran lower than in the third quarter, which fits the broader picture of profitability concentrated in the first part of the calendar year.
For readers tracking the company's first full year of GAAP profit, the practical point is that the expected milestone rests on results already banked. The guidance range still sits comfortably in profit for the year even with the implied final-quarter loss.
Why the Star Rating Matters Here
The release highlighted that the flagship PPO received the top Star Rating for a coming payment year. The Centers for Medicare and Medicaid Services publishes these ratings each year to assess the quality of health and prescription drug services delivered to people enrolled in Medicare Advantage and Part D plans. Each measure receives between one star and the top score based on cut points that the agency recalculates annually, and overall ratings for plans with drug coverage are a weighted average of the measure scores.
The CMS fact sheet states that the newest ratings affect quality Bonus payments in a following year, and that they are displayed for the current open enrollment season, which runs from mid-October to early December. That timing explains why the company's release pairs its rating with a comment that its annual enrollment period is tracking well. A rating can influence both near-term consumer choice and later payment levels, so it touches enrollment and revenue on different schedules.
Scarcity makes the achievement more notable this cycle. According to market data, fewer Medicare Advantage contracts earned the top score than in the prior year, and listed the Clover contract among that small group, with availability in Georgia, New Jersey, Pennsylvania, South Carolina and Texas. CMS said that a little more than a third of rated contracts reached the high-rating threshold, a smaller proportion than last year according to market data, and that the enrollment-weighted average rating slipped slightly.
CMS also changed the rating formula this cycle. It added new Part D measures on concurrent opioid and benzodiazepine use and on use of multiple anticholinergic medications in older adults. It increased the weight of measures on improving or maintaining physical and mental health, while retiring others. Toy tied the rating to the company's clinical software, saying "Through Clover Assistant," the company is "committed to delivering better clinical quality and lower total cost of care," and he also cited a third consecutive year of what the company calls nation-leading HEDIS performance.
A Moving Medicare Advantage Backdrop
The results land in a Medicare Advantage market that federal officials expect to keep growing. According to American Hospital Association News, CMS projected in late September that Medicare Advantage enrollment would rise next year and reach close to half of all Medicare enrollees. The agency also projected that weighted average Medicare Advantage premiums would fall, and that access would remain stable, with nearly all beneficiaries having at least one plan available.
These projections describe the market as a whole and do not address any single insurer's prospects. They do clarify the competitive setting: lower average premiums and broad plan availability mean consumers can compare numerous Options during enrollment, and quality ratings appear next to benefits and costs on the Medicare Plan Finder. A highly rated plan may benefit from that visibility, though the release does not quantify any such effect.
Clover Health focuses on wide-network PPO plans, alongside HMO offerings, in several states. The company describes its mission as improving Medicare access, especially for seniors who have historically lacked affordable, high-quality care. Its Clover Assistant platform aggregates patient data to support clinical decisions and the early identification and management of chronic disease.
Counterpart and the Balance Sheet
Beyond its insurance plans, the company operates Counterpart Health, a Subsidiary that extends its data-driven technology platform to healthcare providers outside its Medicare Advantage plans. The product, branded Counterpart Assistant, is aimed at external payors and providers. The release does not break out separate results for this unit, so its contribution to the quarter cannot be measured from the published figures. Its adoption is named among the risks in the forward-looking statements.
Liquidity improved over the period. Total cash, cash equivalents and investments rose from the prior-year figure by more than a quarter, and Operating Cash Flow for the year to date was substantial. The Balance Sheet showed total Assets comfortably above total liabilities, with unpaid claims representing a large portion of those liabilities.
The company's cautionary language covers a broad range of issues. It cites legislation and regulation affecting Medicare and medical loss ratios, entry into new markets, management of member and provider networks, maintenance of Star Ratings, cybersecurity, staffing, the timing of growth investments, litigation and general economic conditions such as Inflation and interest rates. The maintenance of ratings deserves particular attention given how concentrated membership is in a single rated contract.
Signals to Watch After the Report
Several items remain open. The company's enrollment season runs into early December, so the outcome of its next membership cycle was not known at the time of the release, beyond management's comment that the period is tracking well on the strength of product positioning in core markets. Actual final-quarter results will test the loss implied by the full-year ranges, and any change in the benefits expense ratio will show whether maturing cohorts behave as management describes.
The verified record is the company's own filing, the federal rating data and the trade press listing, which together describe an insurer that grew quickly, returned to GAAP profit in the quarter and earned a high quality score at a moment when fewer rivals did.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...